148 related articles for article (PubMed ID: 10685444)
1. Microbiological characteristics and susceptibility patterns of strains of Rhodotorula isolated from clinical samples.
Galán-Sánchez F; García-Martos P; Rodríguez-Ramos C; Marín-Casanova P; Mira-Gutiérrez J
Mycopathologia; 1999; 145(3):109-12. PubMed ID: 10685444
[TBL] [Abstract][Full Text] [Related]
2. Drug susceptibility of 64 strains of Rhodotorula sp.
Krzyściak P; Macura AB
Wiad Parazytol; 2010; 56(2):167-70. PubMed ID: 20707302
[TBL] [Abstract][Full Text] [Related]
3. Experimental evaluation of antifungal and antiseptic agents against Rhodotorula spp.
Preney L; Théraud M; Guiguen C; Gangneux JP
Mycoses; 2003 Dec; 46(11-12):492-5. PubMed ID: 14641623
[TBL] [Abstract][Full Text] [Related]
4. Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates.
Zaas AK; Boyce M; Schell W; Lodge BA; Miller JL; Perfect JR
J Clin Microbiol; 2003 Nov; 41(11):5233-5. PubMed ID: 14605170
[TBL] [Abstract][Full Text] [Related]
5. Activities of available and investigational antifungal agents against rhodotorula species.
Diekema DJ; Petroelje B; Messer SA; Hollis RJ; Pfaller MA
J Clin Microbiol; 2005 Jan; 43(1):476-8. PubMed ID: 15635020
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility of 245 yeast isolates to amphotericin B, 5-fluorocytosine, ketoconazole, fluconazole and itraconazole.
Martín E; Parras P; Lozano MC
Chemotherapy; 1992; 38(5):335-9. PubMed ID: 1337508
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review.
Gomez-Lopez A; Mellado E; Rodriguez-Tudela JL; Cuenca-Estrella M
J Antimicrob Chemother; 2005 Mar; 55(3):312-6. PubMed ID: 15695538
[TBL] [Abstract][Full Text] [Related]
8. Molecular identification and antifungal susceptibility testing of Pucciniomycotina red yeast clinical isolates from Rio de Janeiro, Brazil.
Brito-Santos F; Figueiredo-Carvalho MHG; Coelho RA; de Oliveira JCA; Monteiro RV; da Silva Chaves AL; Almeida-Paes R
Braz J Microbiol; 2020 Mar; 51(1):95-98. PubMed ID: 31776863
[TBL] [Abstract][Full Text] [Related]
9. [Determination of the in vitro antifungal susceptibility of clinically important yeasts using the Sensititre system].
Carrillo-Muñoz AJ; Quindós G; Gasser I; Tur-Tur C; Ruesga MT; Alonso-Vargas R; Arévalo P; Bornay-Llinares FJ; Santos P; del Valle O
Rev Esp Quimioter; 1999 Jun; 12(2):126-35. PubMed ID: 10562673
[TBL] [Abstract][Full Text] [Related]
10. Rhodotorula minuta as onychomycosis agent in a Chinese patient: first report and literature review.
Zhou J; Chen M; Chen H; Pan W; Liao W
Mycoses; 2014 Mar; 57(3):191-5. PubMed ID: 24118107
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of the isolation of Candida species from hospitalized patients.
Magalhães YC; Bomfim MR; Melônio LC; Ribeiro PC; Cosme LM; Rhoden CR; Marques SG
Braz J Microbiol; 2015 Mar; 46(1):117-23. PubMed ID: 26221096
[TBL] [Abstract][Full Text] [Related]
12. Virulence and antifungal therapy of murine disseminated infection by Rhodotorula mucilaginosa.
Thomson P; López-Fernández L; Guarro J; Capilla J
Diagn Microbiol Infect Dis; 2017 Sep; 89(1):47-51. PubMed ID: 28669678
[TBL] [Abstract][Full Text] [Related]
13. Isolation of Rhodotorula mucilaginosa from blood cultures in a tertiary care hospital.
Falces-Romero I; Cendejas-Bueno E; Romero-Gómez MP; García-Rodríguez J
Mycoses; 2018 Jan; 61(1):35-39. PubMed ID: 28922488
[TBL] [Abstract][Full Text] [Related]
14. Clinical and microbiological characteristics of Rhodotorula mucilaginosa infections in a tertiary-care facility.
Capoor MR; Aggarwal S; Raghvan C; Gupta DK; Jain AK; Chaudhary R
Indian J Med Microbiol; 2014; 32(3):304-9. PubMed ID: 25008826
[TBL] [Abstract][Full Text] [Related]
15. In Vitro Interactions of Amphotericin B Combined with Non-antifungal Agents Against Rhodotorula mucilaginosa Strains.
Spader TB; Ramírez-Castrillón M; Valente P; Alves SH; Severo LC
Mycopathologia; 2019 Feb; 184(1):35-43. PubMed ID: 30632048
[TBL] [Abstract][Full Text] [Related]
16. Rhodotorula spp. isolated from blood cultures: clinical and microbiological aspects.
De Almeida GM; Costa SF; Melhem M; Motta AL; Szeszs MW; Miyashita F; Pierrotti LC; Rossi F; Burattini MN
Med Mycol; 2008 Sep; 46(6):547-56. PubMed ID: 19180725
[TBL] [Abstract][Full Text] [Related]
17. [In vitro susceptibility to antifungal agents of Candida strains isolated from patients with various diseases of the respiratory tract].
Batura-Gabryel H; Wieczorek U; Mlynarczyk W
Pneumonol Alergol Pol; 1997; 65(5-6):355-9. PubMed ID: 9340063
[TBL] [Abstract][Full Text] [Related]
18. Pathogenicity and antifungal susceptibility of Chaetomium species.
Guarro J; Soler L; Rinaldi MG
Eur J Clin Microbiol Infect Dis; 1995 Jul; 14(7):613-8. PubMed ID: 7588850
[TBL] [Abstract][Full Text] [Related]
19. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
20. Identification, antifungal susceptibility and scanning electron microscopy of a keratinolytic strain of Rhodotorula mucilaginosa: a primary causative agent of onychomycosis.
da Cunha MM; dos Santos LP; Dornelas-Ribeiro M; Vermelho AB; Rozental S
FEMS Immunol Med Microbiol; 2009 Apr; 55(3):396-403. PubMed ID: 19170752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
